The nonlinear relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease

被引:3
|
作者
Hu, Yingying [1 ,2 ]
Zhou, Fan [3 ,4 ]
Lei, Fang [2 ,5 ]
Lin, Lijin [1 ,2 ]
Huang, Xuewei [6 ]
Sun, Tao [1 ,2 ]
Liu, Weifang [1 ,2 ]
Zhang, Xingyuan [2 ,5 ]
Cai, Jingjing [2 ,6 ]
She, Zhi-Gang [1 ,2 ]
Li, Hongliang [1 ,2 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan, Peoples R China
[2] Wuhan Univ, Inst Model Anim, Wuhan, Peoples R China
[3] Yangtze Univ, Huanggang Cent Hosp, Dept Gastroenterol, Huanggang, Peoples R China
[4] Huanggang Inst Translat Med, Huanggang, Peoples R China
[5] Wuhan Univ, Sch Basic Med Sci, Wuhan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Cardiol, Changsha, Peoples R China
来源
基金
美国国家科学基金会;
关键词
metabolic dysfunction-associated fatty liver disease; thyroid function parameters; nonlinear relationship; restricted cubic spline analysis; multivariable-adjusted logistic regression models; STIMULATES LEPTIN SECRETION; FREE TRIIODOTHYRONINE; ADIPOSE-TISSUE; HORMONE; RISK; NAFLD; HYPOTHYROIDISM; PATHOGENESIS; THYROTROPIN; PREVALENCE;
D O I
10.3389/fendo.2023.1115354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease (MAFLD) remains controversial. Additionally, little is known about the relationship between thyroid function parameters and MAFLD in the Chinese population. MethodsWe conducted a retrospective cross-sectional study involving 177,540 individuals with thyroid function tests and MAFLD diagnosis from 2010-2018. The association between thyroid function parameters and MAFLD was evaluated on a continuous scale with restricted cubic spline (RCS) models and by the prior-defined centile categories with multivariable-adjusted logistic regression models. Thyroid function parameters included free triiodothyronine (FT3), free tetra-iodothyronine (FT4), and thyroid stimulating hormone (TSH). Additionally, fully adjusted RCS models stratified by sex, age, and location were studied. ResultsIn the RCS models, the risk of MAFLD increased with higher levels of FT3 when FT3 <5.58pmol/L, while the risk of MAFLD decreased with higher levels of FT3 when FT3 >= 5.58pmol/L (P nonlinearity <0.05). While RCS analysis suggested that the FT4 levels had a negative association with MAFLD (P nonlinearity <0.05), indicating an increase in FT4 levels was associated with a decreased risk of MAFLD. RCS analysis suggested an overall positive association between the concentration of TSH and MAFLD risk (P nonlinearity <0.05). The rising slope was sharper when the TSH concentration was less than 1.79uIU/mL, which indicated the association between TSH and MAFLD risk was tightly interrelated within this range. The multivariable logistic regression showed that populations in the 81st-95th centile had the highest risk of MAFLD among all centiles of FT3/TSH, with the 1st-5th centile as the reference category. ConclusionsOur study suggested nonlinear relationships between thyroid function parameters and MAFLD. Thyroid function parameters could be additional modifiable risk factors apart from the proven risk factors to steer new avenues regarding MAFLD prevention and treatment.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Association of metabolic dysfunction-associated fatty liver disease with kidney disease
    Ting-Yao Wang
    Rui-Fang Wang
    Zhi-Ying Bu
    Giovanni Targher
    Christopher D. Byrne
    Dan-Qin Sun
    Ming-Hua Zheng
    Nature Reviews Nephrology, 2022, 18 : 259 - 268
  • [32] The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
    Barrera, Francisco
    Uribe, Javier
    Olvares, Nixa
    Huerta, Paula
    Cabrera, Daniel
    Romero-Gomez, Manuel
    ANNALS OF HEPATOLOGY, 2024, 29 (04)
  • [33] Association of metabolic dysfunction-associated fatty liver disease with kidney disease
    Wang, Ting-Yao
    Wang, Rui-Fang
    Bu, Zhi-Ying
    Targher, Giovanni
    Byrne, Christopher D.
    Sun, Dan-Qin
    Zheng, Ming-Hua
    NATURE REVIEWS NEPHROLOGY, 2022, 18 (04) : 259 - 268
  • [34] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    Han, A. Lum
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):
  • [35] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    A Lum Han
    Diabetology & Metabolic Syndrome, 14
  • [36] The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population
    Seo, Ji Yeon
    Cho, Eun Ju
    Kim, Min Joo
    Kwak, Min-Sun
    Yang, Jong In
    Chung, Su Jin
    Yim, Jeong Yoon
    Yoon, Ji Won
    Chung, Goh Eun
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2022, 13 (06) : 2953 - 2960
  • [37] Association between metabolic dysfunction-associated fatty liver disease and abdominal aortic aneurysm
    Jia, Yu
    Li, Yizhou
    Yu, Jing
    Jiang, Wenli
    Liu, Yi
    Zeng, Rui
    Wan, Zhi
    Liao, Xiaoyang
    Li, Dongze
    Zhao, Qian
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2024, 34 (04) : 953 - 962
  • [38] Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis
    Kim, Donghee
    Dennis, Brittany B.
    Cholankeril, George
    Ahmed, Aijaz
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 329 : 184 - 191
  • [39] Correlation between thyroid function, sensitivity to thyroid hormones and metabolic dysfunction-associated fatty liver disease in euthyroid subjects with newly diagnosed type 2 diabetes
    Xiaodan Zhang
    Yimei Chen
    Huiyu Ye
    Zirui Luo
    Jiahong Li
    Zhishan Chen
    Enting Zhang
    Wangen Li
    Endocrine, 2023, 80 : 366 - 379
  • [40] Correlation between thyroid function, sensitivity to thyroid hormones and metabolic dysfunction-associated fatty liver disease in euthyroid subjects with newly diagnosed type 2 diabetes
    Zhang, Xiaodan
    Chen, Yimei
    Ye, Huiyu
    Luo, Zirui
    Li, Jiahong
    Chen, Zhishan
    Zhang, Enting
    Li, Wangen
    ENDOCRINE, 2023, 80 (02) : 366 - 379